(Q36839703)

16 August 2017

1 reference

title

Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination (English)

1 reference

16 August 2017

6

George G Zhanel

1 reference

16 August 2017

3

James A Karlowsky

1 reference

16 August 2017

Alfred Gin

1

1 reference

16 August 2017

Leanne Dilay

series ordinal

2

1 reference

16 August 2017

Andrew Walkty

series ordinal

4

1 reference

16 August 2017

Ethan Rubinstein

series ordinal

5

1 reference

16 August 2017

publication date

1 June 2007

1 reference

Expert Review of Anti-infective Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

5

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

365-383

1 reference

Clinical role of beta-lactam/beta-lactamase inhibitor combinations

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Recent developments in beta lactamases and extended spectrum beta lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

21 January 2018

The new beta-lactamases.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Penicillins. A current review of their clinical pharmacology and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Class A beta-lactamases--enzyme-inhibitor interactions and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Beta-lactam antibiotic resistance: a current structural perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Inhibition of Cell Division of Escherichia coli by a New Synthetic Penicillin, Piperacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro activities of piperacillin against beta-lactamase-negative ampicillin-resistant Haemophilus influenzae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Resistance to beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Efflux-mediated antimicrobial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Trends in antimicrobial susceptibility in UK centres: the MYSTIC Programme (1997-2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Extended-spectrum beta-lactamases and clinical outcomes: current data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Extended-spectrum beta-lactamases: a clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Plasmid-determined AmpC-type beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In Vitro Susceptibilities of Gram-Negative Bacteria Isolated from Hospitalized Patients in Four European Countries, Canada, and the United States in 2000-2001 to Expanded-Spectrum Cephalosporins and Comparator Antimicrobials: Implications for Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Comparative antianaerobic activity of BMS 284756

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Safety and tolerability of ertapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Continuous infusion beta-lactams for intensive care unit pulmonary infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North Ame

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Comparative in vitro potency of amoxycillin–clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In-vitro activity of cefepime and seven other antimicrobial agents against 1518 non-fermentative Gram-negative bacilli collected from 48 Canadian health care facilities. Canadian Afermenter Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro activity of three different antimicrobial agents against ESBL producing Escherichia coli and Klebsiella pneumoniae blood isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro anti-anaerobic activity of the cephalosporin derivative RWJ 54428, compared to seven other compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Ertapenem: review of a new carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Comparison of Intravenous/Oral Ciprofloxacin Plus Metronidazole Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.365

21 January 2018

Identifiers

DOI

10.1586/14787210.5.3.365

1 reference

16 August 2017

1 reference